Biomarin Pharmaceutical Inc. (BMRN) Stock Has More Upside Than Fundamentals Suggest
Wells Fargo raised the price target for the Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) stock to “an Overweight”. The rating was released on November 15, 2023, according to finviz. The stock was initiated by UBS, who disclosed in a research note on September 18, 2023, to Buy and set the price objective to $120. In their research […]
